Katia Ramos Moreira Leite1,2, Ruan Pimenta3, Juliana Canavez4, Flavio Canavez4, Fernando R de Souza4, Ligia Vara4, Carmen Estivallet4, Luiz Heraldo Camara-Lopes4. 1. Genoa/LPCM Laboratory, São Paulo, Brazil, katiaramos@usp.br. 2. Laboratório de Investigação Médica, Disciplina de Urologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, katiaramos@usp.br. 3. Laboratório de Investigação Médica, Disciplina de Urologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil. 4. Genoa/LPCM Laboratory, São Paulo, Brazil.
Abstract
BACKGROUND: Nearly 500,000 new cases of cervical cancer are estimated annually worldwide. Three vaccines are currently licensed to prevent cervical cancer. The success of vaccination depends mainly on the prevalence of HPV genotypes, and many cases of HPV infection have been diagnosed after vaccination. Our aim was to search for HPV genotyping in cervical samples to verify the proportion of women that remain susceptible to infection even after vaccination. METHODS: 21,017 liquid-based cervical (LBC) specimens were received for cytology and HPV detection from 2015 to 2018. Before slide preparations for cytology, a 1,000-μL aliquot was taken from the LBC fixative and subjected to automated DNA extraction and multiplex PCR followed by capillary electrophoresis to detect and classify HPV. RESULTS: HPV was detected in 895 (4.3%) specimens. The most prevalent genotype was HPV-16, followed by HPV-58 and HPV-66. A total of 258 (28.8%) cases were positive for high-risk (HR)-HPV types (66, 59, 39, 56, 30, 35, 53, 51, 68, 82, and 70) that are not covered by the HPV vaccines. CONCLUSION: A significant proportion of HPV types detected in cytological specimens are representative of HR-HPV not covered by the available vaccines. The health system should be aware of the considerable percentage of women who are not being immunized and will continue to need cervical cancer screening.
BACKGROUND: Nearly 500,000 new cases of cervical cancer are estimated annually worldwide. Three vaccines are currently licensed to prevent cervical cancer. The success of vaccination depends mainly on the prevalence of HPV genotypes, and many cases of HPV infection have been diagnosed after vaccination. Our aim was to search for HPV genotyping in cervical samples to verify the proportion of women that remain susceptible to infection even after vaccination. METHODS: 21,017 liquid-based cervical (LBC) specimens were received for cytology and HPV detection from 2015 to 2018. Before slide preparations for cytology, a 1,000-μL aliquot was taken from the LBC fixative and subjected to automated DNA extraction and multiplex PCR followed by capillary electrophoresis to detect and classify HPV. RESULTS: HPV was detected in 895 (4.3%) specimens. The most prevalent genotype was HPV-16, followed by HPV-58 and HPV-66. A total of 258 (28.8%) cases were positive for high-risk (HR)-HPV types (66, 59, 39, 56, 30, 35, 53, 51, 68, 82, and 70) that are not covered by the HPV vaccines. CONCLUSION: A significant proportion of HPV types detected in cytological specimens are representative of HR-HPV not covered by the available vaccines. The health system should be aware of the considerable percentage of women who are not being immunized and will continue to need cervical cancer screening.
Authors: Daniel Beilner; Christina Kuhn; Bernd P Kost; Julia Jückstock; Doris Mayr; Elisa Schmoeckel; Christian Dannecker; Sven Mahner; Udo Jeschke; Helene Hildegard Heidegger Journal: J Cancer Res Clin Oncol Date: 2020-07-28 Impact factor: 4.553